Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial.

X, Forns; E, Lawitz; S, Zeuzem; E, Gane; JP, Bronowicki; P, Andreone; A, Horban; A, Brown; M, Peeters; O, Lenz; S, Ouwerkerk-Mahadevan; J, Scott; La Rosa G, De; R, Kalmeijer; R, Sinha; M, Beumont-Mauviel

doi:10.1053/j.gastro.2014.02.051

Public

Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial.

Shared by NobleBlocks on Mar 3, 2014 • 12:00 AM UTC

Authors:

Forns X

Lawitz E

Zeuzem S

Abstract

<h4>Background & aims</h4>Simeprevir is an oral, once-daily inhibitor of hepatitis c virus (HCV) protease NS3/4A. We investigated the safety and efficacy of simeprevir with peg-interferon α-2a and ribavirin (PR) in a randomized, double-blind, placebo-controlled, phase 3 trial of patients with HCV ge...

Subject

Drug

Chronic hepatitis C

Daa

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!